http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016513961-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12M1-34 |
| filingDate | 2014-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2016513961-A |
| titleOfInvention | Method for detecting bladder cancer |
| abstract | Compositions and methods for detecting bladder cancer are provided. In some embodiments, a method for detecting low grade bladder cancer is provided. In some embodiments, a method of monitoring recurrence of bladder cancer is provided. The method includes detecting androgen acceptor (AR) and / or uroplakin 1B (UPK1B). Also provided is a method of monitoring therapy using an androgen acceptor antagonist by determining AR and / or UPK1B expression. In some embodiments, the expression is determined in a urine sample. [Selection figure] None |
| priorityDate | 2013-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 446.